The US based biotech firm said that its synthetic Antibody treatment designed to combat covid-19 may be ineffective on the Omicron variant. It further said that it needs to conduct study on how much effective the synthetic treatment will be.
According to the data of REGEN-OCV, neutralization of both vaccine induced and monoclonal Antibody conveyed immunity including the current REGEN-COV antibodies will be less for acting on the new variant. The REGEN-COV is authorized in US as a post-exposure prophylaxis who are facing severe illness due to covid-19. The REGEN-COV is yet to be approved by the FDA.
The WHO in September has authorized Regeneron for treating Covid-19 patients with its REGEN-COV. It has authorized its use for people have specific health profiles and the individual whole immunity is weakened severely.Today the US FDA has amended the emergency use of authorization for Pfizer’s Covid-19 vaccine to administer to 16 and 17 age individuals. The booster does for 17 and 16 age individuals will be given only if they have completed at least six months of primary vaccination with Pfizer’s COVID-19 Vaccine.
Be First to Comment